BioMed Research International / 2014 / Article / Tab 2

Research Article

Comparison of Commercial Genetic-Testing Services in Korea with 23andMe Service

Table 2

Comparison of relative risks among 3 genetic tests.

CategoryRelative risk for participant 1 (man)Relative risk for participant 2 (woman)
Hellogene PlatinumDNAGPS Optimus23andMeHellogene PlatinumDNAGPS Optimus23andMe

Lung cancer2.091.970.8*2.090.920.8*
Esophageal squamous cell carcinoma1.252.411.210.720.520.8
Colorectal caner1.360.731.1 0.980.971.1
Bladder cancer0.770.8Typical 0.770.9Typical/lower
Breast cancerNANANA0.840.770.98
Atopic dermatitis1.161.13Typical1.160.74Lower
Rheumatoid arthritisNANA0.71 0.972.951.1
Systemic lupus erythematosusNANANA 0.971.471.09
Psoriasis0.970.460.87* 0.691.060.44*
Diabetes mellitus, type 10.770.970.08**
Body mass index (obesity)0.910.85* 0.91 0.83*
Atrial fibrillation0.940.681.12* 0.941.391.93*
Coronary artery disease1.060.510.78* 0.620.340.71*
Parkinson's disease1.090.841.050.951.040.77
Narcolepsy1.411.29 Lower*1.411.29 Typical*
Warfarin maintenance doseNormal doseModerate doseDecreased doseNormal doseIncreased doseSlightly decreased dose

NA: not applicable.
*Relative risk in European. There was no Asian data.

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.